EndoChoice Holdings, Inc. is a medical device company. The Company is focused on designing and commercializing a platform of products and services for gastrointestinal (GI) caregivers. The Company offers a range of products and services that span single-use devices and infection control products, pathology and imaging systems. The Company's products are used in colonoscopy and procedures of the upper GI tract, including esophagogastroduodenoscopy (EGD). The Company's imaging products include Fuse system, EndoCart, and Endoscope repair and maintenance. The Company's single-use therapeutic devices include Neptune injection needle, Boa polypectomy snare, Rescue retrieval devices, Blox bite block, TrapEase polyp traps, Hydra irrigation system, EndoGlide+, Compliance EndoKit, SafeStart, EndoKit, CinchPad and GI pathology. The Company serves over 2,500 GI departments that perform endoscopic procedures.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Appliances & Equipment
- Sub-Industry: N/A
- Symbol: NYSE:GI
- CUSIP: N/A
- Web: www.endochoice.com
- 50 Day Moving Avg: $8.00
- 200 Day Moving Avg: $7.14
- 52 Week Range: $3.64 - $8.03
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -6.35
- P/E Growth: 0.00
- Net Margins: -95.68%
- Return on Equity: -83.69%
- Return on Assets: -45.04%
- Debt-to-Equity Ratio: 0.93%
- Current Ratio: 3.95%
- Quick Ratio: 3.09%
Frequently Asked Questions for EndoChoice Holdings (NYSE:GI)
What is EndoChoice Holdings' stock symbol?
EndoChoice Holdings trades on the New York Stock Exchange (NYSE) under the ticker symbol "GI."
How were EndoChoice Holdings' earnings last quarter?
EndoChoice Holdings Inc (NYSE:GI) issued its earnings results on Wednesday, May, 4th. The company reported ($0.68) EPS for the quarter, missing analysts' consensus estimates of ($0.55) by $0.13. The firm earned $18.46 million during the quarter, compared to analysts' expectations of $18.34 million. EndoChoice Holdings had a negative net margin of 95.68% and a negative return on equity of 83.69%. The business's revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.00) EPS. View EndoChoice Holdings' Earnings History.
Where is EndoChoice Holdings' stock going? Where will EndoChoice Holdings' stock price be in 2017?
3 analysts have issued 1 year target prices for EndoChoice Holdings' shares. Their forecasts range from $7.00 to $7.00. On average, they anticipate EndoChoice Holdings' share price to reach $7.00 in the next year. View Analyst Ratings for EndoChoice Holdings.
Who are some of EndoChoice Holdings' key competitors?
Some companies that are related to EndoChoice Holdings include Medtronic plc. (MDT), Abbott Laboratories (ABT), Stryker (SYK), Boston Scientific (BSX), Intuitive Surgical (ISRG), Zimmer Biomet Holdings (ZBH), Edwards Lifesciences Corp (EW), Smith & Nephew plc (SNN), Hologic (HOLX), Align Technology (ALGN), ResMed (RMD), Varian Medical Systems (VAR), Steris PLC (STE), ABIOMED (ABMD), Masimo (MASI), NuVasive (NUVA), Globus Medical (GMED) and Wright Medical Group (WMGI).
When did EndoChoice Holdings IPO?
(GI) raised $101 million in an IPO on Friday, June 5th 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan, BofA Merrill Lynch, William Blair and Stifel served as the underwriters for the IPO.
How do I buy EndoChoice Holdings stock?
Shares of EndoChoice Holdings can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of EndoChoice Holdings stock cost?
One share of EndoChoice Holdings stock can currently be purchased for approximately $8.00.
Earnings History for EndoChoice Holdings (NYSE:GI)Earnings History by Quarter for EndoChoice Holdings (NYSE:GI)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/4/2016||Q116||($0.55)||($0.68)||$18.34 million||$18.46 million||View||N/A|
|3/3/2016||Q415||($0.58)||($0.53)||$19.05 million||$18.50 million||View||N/A|
|11/5/2015||Q315||($0.54)||($0.47)||$18.42 million||$18.40 million||View||N/A|
|8/6/2015||Q215||($0.85)||($0.60)||$17.59 million||$18.60 million||View||N/A|
Earnings Estimates for EndoChoice Holdings (NYSE:GI)
2017 EPS Consensus Estimate: ($2.00)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for EndoChoice Holdings (NYSE:GI)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for EndoChoice Holdings (NYSE:GI)
Insider Ownership Percentage: 31.50%Insider Trades by Quarter for EndoChoice Holdings (NYSE:GI)
Institutional Ownership Percentage: 37.32%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|3/16/2016||Mark Gilreath||CEO||Buy||20,000||$5.06||$101,200.00|| |
|3/15/2016||Mark Gilreath||CEO||Buy||5,018||$5.02||$25,190.36|| |
|3/11/2016||David L Kaufman||Director||Buy||89,450||$4.81||$430,254.50|| |
|3/10/2016||David N Gill||CFO||Buy||2,000||$4.70||$9,400.00|| |
|3/10/2016||William R Enquist||Director||Buy||10,000||$4.74||$47,400.00|| |
|3/8/2016||J Scott Carter||Director||Buy||21,600||$4.72||$101,952.00|| |
|3/7/2016||David N Gill||CFO||Buy||5,000||$4.77||$23,850.00|| |
Headline Trends for EndoChoice Holdings (NYSE:GI)
Latest Headlines for EndoChoice Holdings (NYSE:GI)
|ENDOCHOICE HOLDINGS, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of Delisting|
biz.yahoo.com - November 22 at 5:03 PM
|Boston Scientific Closes EndoChoice Acquisition - PR Newswire (press release)|
www.prnewswire.com - November 22 at 8:41 AM
|Boston Scientific Closes EndoChoice Acquisition|
finance.yahoo.com - November 22 at 8:41 AM
|ENDOCHOICE HOLDINGS, INC. Financials|
finance.yahoo.com - November 16 at 5:29 PM
|ENDOCHOICE HOLDINGS, INC. Files SEC form 10-Q, Quarterly Report|
biz.yahoo.com - November 8 at 12:08 AM
|Boston Scientific Announces Extension of the Cash Tender Offer for All Shares of EndoChoice - PR Newswire (press release)|
www.prnewswire.com - November 4 at 10:05 PM
|Boston Scientific Announces Extension of the Cash Tender Offer for All Shares of EndoChoice|
finance.yahoo.com - November 4 at 6:41 AM
|Boston Scientific Raises Full-Year Outlook|
www.wsj.com - October 27 at 9:52 AM
|4 Medical Device Stocks on a Bull Run this Earnings Season|
finance.yahoo.com - October 26 at 5:16 PM
|Boston Scientific Announces Results For Third Quarter 2016|
finance.yahoo.com - October 26 at 8:20 AM
|ENDOCHOICE SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of EndoChoice Holdings, …|
finance.yahoo.com - October 8 at 9:49 AM
|ENDOCHOICE SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of EndoChoice Holdings, Inc. (GI) Over the Proposed Sale of the Company to Boston Scientific Corporation|
finance.yahoo.com - October 8 at 9:49 AM
|Boston Scientific Commences Cash Tender Offer For All Shares Of EndoChoice For $8.00 Per Share In Cash|
finance.yahoo.com - October 7 at 10:11 AM
|SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of EndoChoice Holdings, Inc. And Encourages Investors To Contact The Firm For Additional ...|
www.businesswire.com - October 1 at 4:46 PM
|SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of EndoChoice Holdings ... - Business Wire (press release)|
www.businesswire.com - September 30 at 5:29 PM
EndoChoice Holdings (GI) Chart for Friday, May, 26, 2017